Lixte Biotechnology Holdings (Nasdaq:LIXT) - 주가, 뉴스 및 분석

LIXT 주식 개요

임상 단계의 제약 회사인 릭스테 바이오테크놀로지 홀딩스는 항암제 개발을 위한 표적 발굴과 암 치료제 개발 및 상용화에 주력하고 있습니다. 자세한 내용

LIXT 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

위험 분석

최근 3개월간 주가 변동폭 심해

의미 있는 시가총액이 없습니다. ( $5M )

수익이 1백만 달러 미만인 경우 ( $0 )

cash runway 경력이 1년 미만입니다.

+ 1 더 많은 위험

Lixte Biotechnology Holdings, Inc. 경쟁사

Oncternal Therapeutics

NasdaqCM:ONCT

US$2.2m

ProtoKinetix

OTCPK:PKTX

US$3.1m

Synaptogenix

NasdaqCM:SNPX

US$3.7m

Theriva Biologics

NYSEAM:TOVX

US$3.6m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Lixte Biotechnology Holdings
과거 주가
현재 주가	US$2.17
52주 최고치	US$4.40
52주 최저치	US$1.31
베타	-0.17
11개월 변경	65.65%
3개월 변경 사항	20.56%
1년 변경 사항	-16.86%
33년 변화	-85.14%
5년 변화	-96.19%
IPO 이후 변화	-95.18%

최근 뉴스 및 업데이트

Recent updates

We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth

Jul 20

Lixte Biotechnology starts enrollment in early-stage lung cancer study

Jun 02

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Feb 25

주주 수익률

	LIXT	US Biotechs	US 마켓
7D	45.6%	4.3%	1.6%
1Y	-16.9%	18.8%	32.3%

수익률 대 산업: LIXT 지난 1년 동안 18.8 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: LIXT 지난 1년 동안 32.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is LIXT's price volatile compared to industry and market?
LIXT volatility
LIXT Average Weekly Movement	21.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

안정적인 주가: LIXT 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: LIXT 의 주간 변동성( 21% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2005	4	Bas van der Baan	lixte.com

임상 단계의 제약 회사인 릭스테 바이오테크놀로지 홀딩스는 항암제 개발을 위한 표적 발굴과 암 치료제의 개발 및 상용화에 주력하고 있습니다. 주요 제품 후보인 LB-100은 미세 위성 안정 전이성 대장암 환자를 대상으로 아테졸리주맙과 병용하는 임상 1b상 시험을 진행 중입니다. 진행성 연조직 육종 임상 1b상에서는 LB-100과 표준 화학 요법을 병용하여 연조직 육종을 치료하기 위한 적절한 용량과 독성을 결정하고, 난소 투명 세포 암종에 대한 1b/2상에서는 LB-100과 도스타리맙을 병용하여 치료하고 있습니다.

Lixte Biotechnology Holdings, Inc. 기본 사항 요약

Lixte Biotechnology Holdings 의 수익과 매출은 시가총액과 어떻게 비교하나요?
LIXT 기본 통계
시가총액	US$4.63m
수익(TTM)	-US$4.00m
수익(TTM)	n/a

0.0x

P/S 비율

-1.2x

P/E 비율

LIXT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
LIXT 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$4.00m
수익	-US$4.00m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.78
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

LIXT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

LIXT 주식 개요

위험 분석

Lixte Biotechnology Holdings, Inc. 경쟁사

NasdaqCM:ONCT

US$2.2m

OTCPK:PKTX

US$3.1m

NasdaqCM:SNPX

US$3.7m

NYSEAM:TOVX

US$3.6m

가격 내역 및 성능

최근 뉴스 및 업데이트

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

Lixte Biotechnology Holdings Receives an Extension Through February 18, 2025 to Regain Compliance with the Stockholders’ Equity Requirement

First Patient Dosed with Lixte Biotechnology Holdings, Inc.’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

New major risk - Share price stability

Recent updates

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

Lixte Biotechnology Holdings Receives an Extension Through February 18, 2025 to Regain Compliance with the Stockholders’ Equity Requirement

First Patient Dosed with Lixte Biotechnology Holdings, Inc.’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

New major risk - Share price stability

Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal

LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Nov 27, 2023

Lixte Biotechnology Holdings, Inc. Announces Chief Executive Officer Changes

LIXTE Biotechnology Holdings, Inc. Announces Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

New minor risk - Shareholder dilution

New major risk - Share price stability

LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol

LIXTE Biotechnology Announces 1-for-10 Reverse Stock Split to Bring it into Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Lixte Biotechnology Holdings, Inc. Announces Recently Published Independent Research Reveals New Mechanisms

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Lixte Biotechnology Holdings, Inc. Promotes Eric Forman to Vice President and Chief Operating Officer

LIXTE Biotechnology Holdings, Inc. Announces Spanish Agency for Medicines and Health Products Authorized Phase 1b/Randomized Phase 2 Study of LB-100

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Oct 07, 2022

Lixte Biotechnology Holdings, Inc. Appoints Bastiaan Van Der Baan as Independent Director

Lixte Biotechnology Holdings, Inc. Appoints Bas Van Der Baan to Its Board of Directors

Lixte Biotechnology Holdings, Inc. Announces Appointment of Professor René Bernards to its Board of Directors

Philip Palmedo Not to Stand for Re-Election as Director of Lixte Biotechnology Holdings, Inc

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Lixte Biotechnology Holdings, Inc. Announces Enrollment Has Resumed in National Cancer Institute’s Trial to Determine Ability of Lixte Compound LB-100 to Enter Recurrent, Malignant Brain Tumors

LixteBiotechnology Holdings, Inc.'s Pre-Clinical Research Demonstrates Inhibition of Protein Phosphatase 2A with LB-100 Combined with the Experimental Drug, Vosoritide

We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth

Lixte Biotechnology Holdings, Inc.(NasdaqCM:LIXT) dropped from Russell 3000E Value Index

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Lixte Biotechnology starts enrollment in early-stage lung cancer study

Independent Director has left the company

Lixte Biotechnology Holdings, Inc. to Showcase Its Anti-Cancer Therapy Enhancer LB-100 At the Virtual Annual Roth Capital Conference

New 90-day high: US$5.58

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

New 90-day low: US$3.05

Lixte Biotechnology Holdings, Inc. and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’S Lead Compound Lb-100 to Treat Small Cell Lung Cancer

New 90-day low: US$3.14

New 90-day low: US$3.59

New 90-day low: US$3.60

New 90-day low: US$3.65

Lixte Biotechnology Holdings Deleted from Other OTC

New 90-day low: US$3.74

Lixte Biotechnology Holdings, Inc. has completed an IPO in the amount of $5.7 million.

Lixte Biotechnology Holdings, Inc. has filed an IPO in the amount of $10.668 million.

주주 수익률

가격 변동성

회사 소개

Lixte Biotechnology Holdings, Inc. 기본 사항 요약

0.0x

-1.2x

수익 및 수익